MDHHS – MCIR Release Notes

Version 2023 - MCIR OLTP 2023 9.4.3.3- RFC 218598

Release Date: May 17, 2023

Forecasting & Assessment Updates

For clinical guidance visit Interim Clinical Considerations for Use of COVID-19 Vaccines in United States & COVID-19 Vaccine Interim Immunization Schedule for Persons 6 Months of Age and Older

Case examples Unvaccinated 2-year-old

• Forecasts for date of updated recommendation for bivalent vaccines. (Ref. ID #2346)

Pfizer/Moderna Bivalent YES	1	04/19/2023	04/19/2023	04/19/2023	
-----------------------------	---	------------	------------	------------	--

History of one monovalent Moderna dose

Previously vaccinated with	n monovale	nt mRNA COVID-19 vaccine		
1 dose of monovalent vac	cine	1 dose. Administer: • Dose 2 at least 4–8 weeks [¶] after Dose 1	0.25 mL/25 µg fr blue cap and gra	om the vial with a ay label border.
2				
1 2 Years	04/18/	2023 MDHHS Nurse Educators	Unknown	Delete
	1 dose of monovalent vac 2 <u>1</u> 2 Years	1 dose of monovalent vaccine 2 10D 1 2 Years 04/18/	1 dose of monovalent vaccine Administer: • Dose 2 at least 4–8 weeks [¶] after Dose 1 2 1 2 Years 04/18/2023 MDHHS Nurse Educators	1 dose of monovalent vaccine 1 dose. Administer: • Dose 2 at least 4–8 weeks [¶] after Dose 1 0.25 mL/25 μg fr blue cap and gra 2 1 2 Years 0/1/18/2023 MDHHS Nurse Educators Linknown

• MCIR forecasts for accelerated 4 weeks after dose 1, 8 weeks after dose 1 for recommended and overdue

Moderna Bivalent 25MCG	YES	2	05/16/2023	06/13/2023	06/13/2023	

History of two Moderna monovalent doses

2 doses of mor	novalent vaccine	1 dose. Administer: • Dose 3 at least 8 weeks (2 months) after Dose 2	0.2 mL/10 μg from the dark pink cap and yel border	
SARS-CoV-2	07/01/2022 11/15// COVID-19 MOD COVID-1 25 mcg ped 25 mcg 6mos 10mos	9 MOD) ped		Moderna Bivalent 10MCG PED DUE NOW

MCIR forecasts for date of updated bivalent recommendation 4/19/23 or 8 weeks after dose 2
 Moderna Bivalent 10MCG PED YES 3 04/19/2023 04/19/2023 04/19/2023

History of one Moderna bivalent dose

Unvaccinated: 0 doses	2 doses. Administer: • Dose 1 now • Dose 2 at least 4–8 weeks [¶] after Dose 1	0.25 mL/25 μg from the vial with a blue cap and gray label border
1 dose of bivalent vaccine	1 dose. Administer: • Dose 2 at least 4–8 weeks [¶] after Dose 1	blue cap and gray laber border
At least 2 doses of bivalent vaccine	No dose	No dose



SARS-CoV-2				
COVID-19 MOD Bivalent Booster 50mcg/0.5mL	1 4 Years 4 Months	05/01/2023 MDHHS Nurse Educators	Unknown	<u>Delete</u>

MCIR forecasts for accelerated as 4 weeks, recommended and overdue at 8 weeks Moderr

rna Bivalent 25MCG	2	05/29/2023	06/26/2023	06/26/2023	

History of two monovalent Moderna doses and one Moderna bivalent dose - up to date

	Up-To-Date
--	------------

History of one monovalent PFR-BNT dose

6 months		atter Dose 2	
through 4 years ^{‡§}	At least 3 doses of bivalent vaccine	No dose	No dose
.,	Previously vaccinated with monovale	nt mRNA COVID-19 vaccine	
	1 dose of monovalent vaccine	2 doses. Administer: • Dose 2 at least 3–8 weeks [¶] after Dose 1 • Dose 3 at least 8 weeks (2 months) after Dose 2	0.2 mL/3 μg from the vial with a
	2 doses of monovalent vaccine	1 dose. Administer: • Dose 3 at least 8 weeks (2 months) after Dose 2	maroon cap
	At least 1 dose of monovalent vaccine and 1 dose of bivalent vaccine	No dose	No dose.
SARS-CoV-	2	-	
COVID-19 F 3mcg/0.2mL	1 3 Years 3 Months (14/0)	I/2023 MDHHS Nurse Educators	Unknown <u>Delete</u>

• Forecast dose 2 at accelerated 3 weeks, 8 weeks recommended and overdue

Pfizer Bivalent 3MCG PED	YES	2	04/22/2023	05/27/2023	05/27/2023	
--------------------------	-----	---	------------	------------	------------	--

History of two doses of monovalent PFR-BNT vaccine

SARS-CoV-2				
COVID-19 PFR- BNT 3mcg/0.2mL	1 4 Years 8 Months	07/18/2022 MDHHS Nurse Educators	Unknown	Delete
COVID-19 PFR- BNT 3mcg/0.2mL	2 4 Years 9 Months	08/16/2022 MDHHS Nurse Educators	Unknown	Delete

Forecasts for date of updated recommendation or 8 weeks after dose 2

Pfizer/Moderna Bivalent YES 3 04/19/2023 04/19/2023 04/19/2023
--

History of three monovalent PFR-BNT doses

	04/01/2022 COVID-19 PFR-	05/01/2022 COVID-19 PFR-	04/01/2023 COVID-19 PFR-	Up-To-Date
SARS-CoV-2	BNT	BNT	BNT	Next Due
	3mcg/0.2mL 2yrs 3mos	3mcg/0.2mL 2yrs 4mos	3mcg/0.2mL 3yrs 3mos	05/27/2023



• Forecast for bivalent vaccine accelerated, recommended and overdue - 8 weeks

Pfizer Bivalent 3MCG PED	4	05/27/2023	05/27/2023	05/27/2023
16796783984				

History	of at least one	monovalent and	l one bivalent dose	e – up to date
1113001	of at icast one	monovaient ana		

,		chie and one biraten	
SARS-CoV-2	COVID-19 PFR- COVID- BNT BI 10mcg/0.2mL 10mcg	1/2022 05/01/2023 -19 PFR- COVID-19 PFR NT Bivalent Booster g/0.2mL 10mcg/0.2mL 4mos 9yrs 7mos	Up-To-Date
SARS-CoV-2	COVID-19 PFR- COVID- BNT B 3mcg/0.2mL 3mcg	0/2022 03/17/2023 -19 PFR- COVID-19 PFR BNT Bivalent Booster g/0.2mL 3mcg/0.2mL 5 5mos 3yrs	Up-To-Date

If you have questions or need assistance, please contact your Field Representative, MCIR Region, or MCIR SOM Help Desk at MDHHS-MCIRHelp@michigan.gov.

